EDSA — Edesa Biotech Cashflow Statement
0.000.00%
- $15.28m
- $12.48m
Annual cashflow statement for Edesa Biotech, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 9 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -2.78 | -6.36 | -13.3 | -17.5 | -8.37 |
Depreciation | |||||
Non-Cash Items | 0.033 | 0.598 | 3.2 | 2.26 | 1.25 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -2.11 | 0.722 | -3.64 | 2.89 | 0.308 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -4.85 | -4.99 | -13.7 | -12.3 | -6.64 |
Capital Expenditures | -0.008 | -0.034 | -0.006 | -0.006 | 0 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 6.43 | 0.053 | 0 | — | — |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 6.42 | 0.019 | -0.006 | -0.006 | 0 |
Financing Cash Flow Items | — | -0.533 | -0.188 | -0.328 | -0.285 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | — | 7.09 | 14.2 | 11.6 | 4.83 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 1.66 | 2.18 | 0.626 | -0.748 | -1.73 |